ClinicalTrials.gg
CompletedNCT03546842Updated Feb 25, 2020Results posted

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

A Phase 3 interventional study of 9vHPV vaccine in Papillomavirus Infections, Uterine Cervical Neoplasms and Vulvar Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Vietnam. Open to participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-25.

Primary conditionCondylomata AcuminataRegistry: Papillomavirus InfectionsReclassifiedWhy we changed it
Registry
Papillomavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Condylomata Acuminata
Why
  1. The study's listed conditions name Condylomata Acuminata, a narrower term within Papillomavirus Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Not applicable
Ages
9 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata — 2 open to participants now, 4 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Condylomata Acuminata.

Enrollment
10th of 10
201 · median 1,206
Started
2018
the only one that year
Phase 3
9 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
6 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 9 in phase 3, and was the 4th registered.

Condylomata Acuminata

116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.

Browse Condylomata Acuminata studies →

Open to participants now

2 of the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Condylomata Acuminata studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 9 Years to 26 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, or all of them as a file.
02

Study summary

This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam. The study hypothesis states that V503 induces acceptable anti-human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion at 4 weeks postdose 3.

03

Conditions studied

  • Papillomavirus Infections
  • Uterine Cervical Neoplasms
  • Vulvar Neoplasms
  • Vaginal Neoplasms
  • Adenocarcinoma in Situ
  • Condylomata Acuminata
04

In context

Condylomata Acuminata Reclassified

116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.

This study's enrollment of 201 is above the median of 158 across 95 interventional studies indexed under Condylomata Acuminata.

Browse Condylomata Acuminata studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Condylomata Acuminata, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Papillomavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
9 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good physical health
  • Participants 9 to 15 years of age: has not had coitarche and do not plan on becoming sexually active during the study
  • Participants 16 to 26 year of age: has never had Papanicolaou (Pap) testing or has had only normal Pap test results. Has a lifetime history of ≤4 male and/or female sexual partners.
  • Female participants 16 to 26 years of age: has not had sex with males or has had sex with males and used effective , and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (rhythm method, withdrawal, and emergency contraception are not acceptable methods of contraception per-protocol).

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any vaccine component, including aluminum, yeast, or BENZONASE™
  • History of severe allergic reaction that required medical intervention
  • Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
  • Concurrently enrolled in clinical studies of agents
  • or has been diagnosed with congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other condition
  • Had a splenectomy
  • User of recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
  • History of a positive test for HPV
  • Male participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata) or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer.
  • Female participants 16 to 26 years of age: history of an abnormal cervical result (showing cervical intraepithelial neoplasia or worse).
  • Female participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata, or vulvar intraepithelial neoplasia) or external genital cancer, HPV-related vaginal lesions (e.g., condyloma acuminata, or vaginal intraepithelial neoplasia) or vaginal cancer, or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer.
  • Female participants: pregnant as determined by a serum pregnancy test or urine pregnancy test that is sensitive to 25 mIU/mL beta human chorionic gonadotropin (β-hCG).
  • Female participants: expecting to donate eggs during the study.
  • Receiving or has received a prohibited immunosuppressive therapy in the year prior to the study
  • Received any immune globulin product or blood-derived product within the 3 months prior to the Day 1 vaccination, or plans to receive any such product during the study
  • Received inactivated or recombinant vaccines within 14 days prior to the Day 1 vaccination or has received within 21 days prior to the Day 1 vaccination
  • Received a marketed HPV vaccine, or has participated in an HPV vaccine clinical study and has received either active agent or placebo
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    9vHPV vaccine

    Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6

    Biological: 9vHPV vaccine

Interventions

  • Biological9vHPV vaccine

    9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection

    Also known as: V503, GARDASIL™9

07

What researchers measure

Primary outcomes

  1. Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7

    Seroconversion was defined as a participant who was anti-HPV seronegative at Day 1 and became seropositive at 4 weeks postdose 3 (Month 7). Anti-HPV antibodies were measured using a Competitive Luminex Immunoassay.

    Time frame: 4 weeks postdose 3 (Month 7)

Secondary outcomes

  1. Percentage of Participants With a Solicited Injection-site Adverse Event

    An adverse event (AE) was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with study vaccine. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the study vaccine or protocol-specified procedure was also an AE. The participant or the parent/guardian of the participant were to record the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 5 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, and swelling) was summarized.

    Time frame: Up to 5 days after any vaccination

  2. Percentage of Participants With a Solicited Systemic Adverse Event

    An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with study vaccine. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the study vaccine or protocol-specified procedure was also an AE. The only solicited systemic AE was in response to results of daily oral temperature assessments. The participant or the parent/guardian of the participant will be asked to record the participant's oral temperature in the evening after each study vaccination and daily for 4 days after each study vaccination on VRC. The percentage of participants that had an AE due to an elevated oral temperature \[(≥ 37.8 °C (100.0 °F)\] was summarized.

    Time frame: Up to 5 days after any vaccination

  3. Percentage of Participants With a Vaccine-related Serious Adverse Event

    A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants that experience at least one SAE that was reported as at least possibly related to the study vaccine was summarized.

    Time frame: Up to 4 weeks postdose 3 (Month 7)

  4. Geometric Mean Titers of Serotype-specific Antibodies: Predose Day 1

    Anti-HPV Type 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies are measured using a Competitive Luminex Immunoassay. Titers are reported in milli Merck units/mL (mMU/mL).

    Time frame: Day 1 (predose)

  5. Geometric Mean Titers of Antibodies to HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7

    Anti-HPV Type 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies are measured using a Competitive Luminex Immunoassay. Titers are reported in mMU/mL.

    Time frame: 4 weeks postdose 3 (Month 7)

08

Results

Posted Feb 5, 2020

Participant flow

Participant flow — Overall Study
Milestone9vHPV Vaccine
Started201
Vaccination 1200
Vaccination 2200
Vaccination 3198
Completed198
Not completed3
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject2

Outcome measures

PrimarySeroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7

Seroconversion was defined as a participant who was anti-HPV seronegative at Day 1 and became seropositive at 4 weeks postdose 3 (Month 7). Anti-HPV antibodies were measured using a Competitive Luminex Immunoassay.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Number · Percentage of Participants
Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7
Percentage of Participants9vHPV Vaccine
Anti-HPV 6100 (98.1 to 100.0)
Anti-HPV 11100 (98.1 to 100.0)
Anti-HPV 16100 (98.0 to 100.0)
Anti-HPV 18100.0 (98.1 to 100.0)
Anti-HPV 31100.0 (98.1 to 100.0)
Anti-HPV 33100.0 (98.1 to 100.0)
Anti-HPV 45100.0 (98.1 to 100.0)
Anti-HPV 52100.0 (98.1 to 100.0)
Anti-HPV 58100.0 (98.1 to 100.0)
SecondaryPercentage of Participants With a Solicited Injection-site Adverse Event

An adverse event (AE) was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with study vaccine. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the study vaccine or protocol-specified procedure was also an AE. The participant or the parent/guardian of the participant were to record the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 5 days after any vaccination. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, and swelling) was summarized.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Solicited Injection-site Adverse Event
Percentage of Participants9vHPV Vaccine
Percentage of Participants With a Solicited Injection-site Adverse Event45.0 (38.0 to 52.2)
SecondaryPercentage of Participants With a Solicited Systemic Adverse Event

An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with study vaccine. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the study vaccine or protocol-specified procedure was also an AE. The only solicited systemic AE was in response to results of daily oral temperature assessments. The participant or the parent/guardian of the participant will be asked to record the participant's oral temperature in the evening after each study vaccination and daily for 4 days after each study vaccination on VRC. The percentage of participants that had an AE due to an elevated oral temperature \[(≥ 37.8 °C (100.0 °F)\] was summarized.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Solicited Systemic Adverse Event
Percentage of Participants9vHPV Vaccine
Percentage of Participants With a Solicited Systemic Adverse Event0.0
SecondaryPercentage of Participants With a Vaccine-related Serious Adverse Event

A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants that experience at least one SAE that was reported as at least possibly related to the study vaccine was summarized.

Time frame:
Up to 4 weeks postdose 3 (Month 7)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Vaccine-related Serious Adverse Event
Percentage of Participants9vHPV Vaccine
Percentage of Participants With a Vaccine-related Serious Adverse Event0.0
SecondaryGeometric Mean Titers of Serotype-specific Antibodies: Predose Day 1

Anti-HPV Type 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies are measured using a Competitive Luminex Immunoassay. Titers are reported in milli Merck units/mL (mMU/mL).

Time frame:
Day 1 (predose)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers of Serotype-specific Antibodies: Predose Day 1
mMU/mL9vHPV Vaccine
Anti-HPV 6NA (NA to NA)
Anti-HPV 11NA (NA to NA)
Anti-HPV 16NA (NA to NA)
Anti-HPV 1829.3 (27.7 to 31.1)
Anti-HPV 31NA (NA to NA)
Anti-HPV 33NA (NA to 8.3)
Anti-HPV 45NA (NA to NA)
Anti-HPV 52NA (NA to NA)
Anti-HPV 58NA (NA to NA)
SecondaryGeometric Mean Titers of Antibodies to HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7

Anti-HPV Type 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies are measured using a Competitive Luminex Immunoassay. Titers are reported in mMU/mL.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers of Antibodies to HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7
mMU/mL9vHPV Vaccine
Anti-HPV 61008.2 (921.9 to 1102.6)
Anti-HPV 11796.3 (722.2 to 878.0)
Anti-HPV 164605.4 (4163.7 to 5093.9)
Anti-HPV 181621.6 (1441.2 to 1824.5)
Anti-HPV 311137.9 (1017.2 to 1273.0)
Anti-HPV 33507.8 (458.5 to 562.4)
Anti-HPV 45579.2 (511.7 to 655.6)
Anti-HPV 52500.8 (450.5 to 556.7)
Anti-HPV 58701.8 (628.5 to 783.7)

Adverse events

Collected over Up to 4 weeks postdose 3 (Month 7). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
9vHPV Vaccine0/201 (0%)1/200 (0.5%)90/200 (45%)
Most frequent serious events
Most frequent serious events
Event9vHPV Vaccine
Subcutaneous abscessInfections and infestations1/200
Most frequent other events
Most frequent other events
Event9vHPV Vaccine
Injection site painGeneral disorders89/200
Injection site swellingGeneral disorders12/200

Baseline characteristics

Age, Continuous
Age, Continuous(years)9vHPV Vaccine
Mean15.8 ± 4.4
Sex: Female, Male
Sex: Female, Male(Participants)9vHPV Vaccine
Female135
Male66
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)9vHPV Vaccine
Hispanic or Latino0
Not Hispanic or Latino201
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)9vHPV Vaccine
American Indian or Alaska Native0
Asian201
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
09

Study locations

1 site
  • National Institute of Hygiene and Epidemiology ( Site 0001)
    Hanoi, 100000, Vietnam
10

References and documents

Publications

  • Thiem VD, Quang ND, Tuan NH, Cheon K, Gallagher N, Luxembourg A, Group T, Badshah C. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial. Hum Vaccin Immunother. 2021 Jul 3;17(7):1980-1985. doi: 10.1080/21645515.2020.1865739. Epub 2021 Apr 12. PubMed 33844623 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jan 2019, 7 months.

Results were first posted in Feb 2020, 1 year after primary completion.

Of 28 phase 3 interventional studies under Condylomata Acuminata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2018
First posted
Jun 6, 2018
StartActual
Jun 29, 2018
Primary completionActual
Jan 29, 2019
CompletionActual
Jan 29, 2019
Results first posted
Feb 5, 2020
Last update
Feb 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03546842
Responsible party
Sponsor
First posted
Jun 6, 2018
Start date
Jun 29, 2018
Primary completion
Jan 29, 2019
Completion
Jan 29, 2019
Results posted
Feb 5, 2020
Last update
Feb 25, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion